Figure 8.

Pharmacological treatment with the TACE inhibitor BMS-561392 ameliorates myelination in DRGs explant cultures. Myelinating DRGs were treated with 1 μm BMS (BMS1) for 2 weeks. As controls, not treated and DMSO-treated DRGs were analyzed. (A) Immunostaining for MBP showing the increase in the number of MBP-positive segments in S63del-treated samples (size bar, 100 μm). Quantification of internode number in (B) WT (see also Supplementary Material, Fig. 8A) and (C) S63del DRGs, normalized to the untreated control. Note how treatment with BMS increases the number of internodes in both the genotypes with similar magnitude. Ten to fifteen DRGs per condition from three independent dissections were analyzed. ^**P < 0.01 and ^***P < 0.001 by one-way ANOVA with Bonferroni’s multiple comparison test; error bars represent SEM.